The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Seed VC | Alive

Total Raised


Last Raised

$2.7M | 8 yrs ago

About Apta Biosciences

Apta Biosciences is a synthetic biology company specializing in developing unique, proprietary molecules that can be used broadly across diagnostics and therapeutics. These facilitate and expand scientific discovery enabling the development of new healthcare solutions.

Apta Biosciences Headquarter Location

The Elms Courtyard Bromesberrow

Ledbury, HR8 1RZ,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Apta Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Apta Biosciences is included in 2 Expert Collections, including Synthetic Biology.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.


Biopharma Tech

838 items

Apta Biosciences Patents

Apta Biosciences has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Drug delivery devices, Gas technologies, Dosage forms, Surface science, MicroRNA


Application Date


Grant Date



Related Topics

Drug delivery devices, Gas technologies, Dosage forms, Surface science, MicroRNA



Latest Apta Biosciences News

Apta Biosciences Awarded H2020 EU Grant to Incorporate Seligo Technology into Next Generation Antibiotics and Infectious Disease Therapeutics

Nov 4, 2015

| Print | Wednesday, 04 November 2015 09:15 (UTC + 1) London, UK, November 4, 2015 / B3C newswire / --  Apta Biosciences Ltd , is pleased to announce that it has been awarded an H2020 grant from the European Union in collaboration with the Austrian Institute of Technology (Vienna, Austria), Imperial College (London, UK), Aarhus University (Aarhus, Denmark) and Albert-Ludwigs University (Freiburg, Germany) to use its Seligo technology  in the  the project whose long term goals are antibiotic replacements for infectious diseases. The overall grant is over €3 million of which Apta will receive €940 thousand. The programme called MARA combines three novel technologies to create a DNA-based molecular toolkit for the characterisation of pathogens. First, the detection of pathogen-associated antigens will be performed by Autonomous Detection Nucleic Acids (AUDENA) that are independent of any laboratory instruments and sophisticated processing. The realisation of the AUDENA concept will lead to an autonomous, stable, simple and very economic novel sensor class applicable for any water-soluble substances. Second, a novel approach in protein mimicry and creation of artificial enzymes. Third, the development of a molecular drill that can specifically identify target cells and destroy them. This Molecular Robot (MORO) will be made of self-assembling DNA. The MORO will be used for the lysis of bacterial cells to release intracellular antibiotic resistance associated antigens. Using specially designed, artificial molecular machines for a highly targeted attack on pathogens or tumour cells may well cause a paradigm shift in our approach to disease therapy and open up a whole new area in molecular medicine. About Apta Biosciences Apta Biosciences (ABS) is a biotech SME that has developed a unique targeting and detection technology called Seligo that combines the strengths of DNA structural integrity with the flexibility of antibodies. In the course of the programme Seligo will be designed that specifically detect antigens for the AUDENA section and secondly, Seligo that tether the MORO to the pathogens or tumour cells so facilitating the cell lysis. For more information on Apta Biosciences or the project, please contact:

Apta Biosciences Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Apta Biosciences Rank

  • Where is Apta Biosciences's headquarters?

    Apta Biosciences's headquarters is located at The Elms Courtyard, Ledbury.

  • What is Apta Biosciences's latest funding round?

    Apta Biosciences's latest funding round is Seed VC.

  • How much did Apta Biosciences raise?

    Apta Biosciences raised a total of $2.7M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.